Literature DB >> 10513714

Intoxication due to negative canrenone interference in digoxin drug monitoring.

W Steimer, C Müller, B Eber, K Emmanuilidis.   

Abstract

Canrenone and spironolactone caused falsely low readings in a common assay for digoxin (AxSym MEIA) due to negative cross-reactivity. Misleading subtarget concentrations were repeatedly reported, and falsely guided drug dosing resulted in a case of digoxin intoxication.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10513714     DOI： 10.1016/S0140-6736(99)03818-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  8 in total

1.  Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay.

Authors:  Amitava Dasgupta; Myrtle J Johnson; Tamal K Sengupta
Journal:  J Clin Lab Anal       Date:  2012-05       Impact factor: 2.352

2.  A new enzyme-linked chemiluminescent immunosorbent digoxin assay is virtually free from interference of spironolactone, potassium canrenoate, and their common metabolite canrenone.

Authors:  Amitava Dasgupta; Edward Kang; Pradip Datta
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

3.  Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.

Authors:  Amitava Dasgupta; Myrtle J Johnson
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

4.  Interferences in immunoassay.

Authors:  Jill Tate; Greg Ward
Journal:  Clin Biochem Rev       Date:  2004-05

5.  LC-MS assay for quantitative determination of cardio glycoside in human blood samples.

Authors:  L Frommherz; H Köhler; B Brinkmann; M Lehr; J Beike
Journal:  Int J Legal Med       Date:  2007-06-14       Impact factor: 2.686

6.  Bidirectional (positive/negative) interference of spironolactone, canrenone, and potassium canrenoate on serum digoxin measurement: elimination of interference by measuring free digoxin or using a chemiluminescent assay for digoxin.

Authors:  Amitava Dasgupta; Helene Saffer; Alice Wells; Pradip Datta
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

7.  Simultaneous identification and quantification of canrenone and 11-α-hydroxy-canrenone by LC-MS and HPLC-UVD.

Authors:  Da-Ming Huang; Tian-Zhen Zhang; Feng-Jie Cui; Wen-Jing Sun; Li-Ming Zhao; Meng-Yi Yang; Ya-Juan Wang
Journal:  J Biomed Biotechnol       Date:  2011-12-13

8.  Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring.

Authors:  Gunilla Englund; Pär Hallberg; Per Artursson; Karl Michaëlsson; Håkan Melhus
Journal:  BMC Med       Date:  2004-04-02       Impact factor: 8.775
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.